Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Recurso digital |
| Hizkuntza: | ingelesa |
| Argitaratua: |
Zenodo
2026
|
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1111/bjh.70367 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1866902173234757632 |
|---|---|
| author | Peña, M. Lazzari, L. Martinez, D.F. Ciceri, F. Balaguer-Roselló, A. Sanz, J. Pascual, M.J. Benzaquén, A. Piñana, J.L. Salas, M.Q. Nieto Vázquez, A. Español, I. Huguet, M. Bento, L. Sáez, A.J. Barba-Suñol, P. Filaferro, S. Carbonell-Asins, J.A. Peña, C. Mussetti, A. Greco, R. |
| author_facet | Peña, M. Lazzari, L. Martinez, D.F. Ciceri, F. Balaguer-Roselló, A. Sanz, J. Pascual, M.J. Benzaquén, A. Piñana, J.L. Salas, M.Q. Nieto Vázquez, A. Español, I. Huguet, M. Bento, L. Sáez, A.J. Barba-Suñol, P. Filaferro, S. Carbonell-Asins, J.A. Peña, C. Mussetti, A. Greco, R. |
| contents | Allogeneic haematopoietic cell transplantation (alloHCT) remains a potentially curative strategy for relapsed or refractory lymphoid malignancies, even in the post-chimeric antigen receptor T-cell and bispecific antibody era. While reduced-intensity conditioning regimens offer lower non-relapse mortality (NRM), relapse rates remain high, and optimal conditioning strategies in the setting of post-transplant cyclophosphamide (PTCy) prophylaxis remain undefined. In this retrospective, international multicentre study, the primary end-point was NRM. We compared treosulfan/fludarabine (Treo/Flu) versus thiotepa/busulfan/fludarabine (TBF) in 178 adults with lymphoid malignancies undergoing first alloHCT with PTCy and peripheral blood grafts. Three-year NRM was 14.0% with Treo/Flu versus 33.0% with TBF. On multivariate analysis, Treo/Flu was associated with significantly lower 3-year NRM (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.22–0.87; p = 0.018). Conditioning regimen was not independently associated with overall survival (OS) or progression-free survival (PFS), and relapse incidence was similar between regimens. Moderate to severe chronic graft-versus-host disease (GVHD) was higher with Treo/Flu (26.0% vs. 9.9%; HR 2.43; 95% CI, 1.09–5.43; p = 0.03), while GVHD-free/relapse-free survival (GFRS) was comparable. Findings were consistent in a prespecified propensity score-matched sensitivity analysis. These findings support Treo/Flu as a potentially safer reduced-toxicity conditioning option than TBF in the context of PTCy-based GVHD prophylaxis for lymphoid malignancies and warrant prospective validation. © 2026 British Society for Haematology and John Wiley & Sons Ltd. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_1111_bjh_70367 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study Peña, M. Lazzari, L. Martinez, D.F. Ciceri, F. Balaguer-Roselló, A. Sanz, J. Pascual, M.J. Benzaquén, A. Piñana, J.L. Salas, M.Q. Nieto Vázquez, A. Español, I. Huguet, M. Bento, L. Sáez, A.J. Barba-Suñol, P. Filaferro, S. Carbonell-Asins, J.A. Peña, C. Mussetti, A. Greco, R. allogeneic haematopoietic cell transplantation lymphoid malignancies post-transplant cyclophosphamide reduced-intensity conditioning treosulfan/fludarabine Allogeneic haematopoietic cell transplantation (alloHCT) remains a potentially curative strategy for relapsed or refractory lymphoid malignancies, even in the post-chimeric antigen receptor T-cell and bispecific antibody era. While reduced-intensity conditioning regimens offer lower non-relapse mortality (NRM), relapse rates remain high, and optimal conditioning strategies in the setting of post-transplant cyclophosphamide (PTCy) prophylaxis remain undefined. In this retrospective, international multicentre study, the primary end-point was NRM. We compared treosulfan/fludarabine (Treo/Flu) versus thiotepa/busulfan/fludarabine (TBF) in 178 adults with lymphoid malignancies undergoing first alloHCT with PTCy and peripheral blood grafts. Three-year NRM was 14.0% with Treo/Flu versus 33.0% with TBF. On multivariate analysis, Treo/Flu was associated with significantly lower 3-year NRM (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.22–0.87; p = 0.018). Conditioning regimen was not independently associated with overall survival (OS) or progression-free survival (PFS), and relapse incidence was similar between regimens. Moderate to severe chronic graft-versus-host disease (GVHD) was higher with Treo/Flu (26.0% vs. 9.9%; HR 2.43; 95% CI, 1.09–5.43; p = 0.03), while GVHD-free/relapse-free survival (GFRS) was comparable. Findings were consistent in a prespecified propensity score-matched sensitivity analysis. These findings support Treo/Flu as a potentially safer reduced-toxicity conditioning option than TBF in the context of PTCy-based GVHD prophylaxis for lymphoid malignancies and warrant prospective validation. © 2026 British Society for Haematology and John Wiley & Sons Ltd. |
| title | Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study |
| topic | allogeneic haematopoietic cell transplantation lymphoid malignancies post-transplant cyclophosphamide reduced-intensity conditioning treosulfan/fludarabine |
| url | https://doi.org/10.1111/bjh.70367 |